We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$310M
AUM Growth
+$8.93M
Cap. Flow
+$4.99M
Cap. Flow %
1.61%
Top 10 Hldgs %
58.2%
Holding
58
New
5
Increased
12
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$13.4M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$7.82M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.27M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.06M
5
XLRN
Acceleron Pharma
XLRN
+$5.28M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.1M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$9.04M
3
ZGNX
Zogenix, Inc.
ZGNX
+$6.17M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMUX icon
26
Immunic
IMUX
$222M
$2.28M 0.74%
12,300
– –
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$2.23M 0.72%
177,433
– –
ASND icon
28
Ascendis Pharma A/S
ASND
$16.4B
$2.13M 0.69%
13,800
– –
IONS icon
29
Ionis Pharmaceuticals
IONS
$10.4B
$1.89M 0.61%
39,781
– –
CRSP icon
30
CRISPR Therapeutics
CRSP
$5.74B
$1.84M 0.59%
22,000
– –
BPMC
31
DELISTED
Blueprint Medicines
BPMC
$1.81M 0.58%
19,500
+7,500
+63% +$578K
AUPH icon
32
Aurinia Pharmaceuticals
AUPH
$2.19B
$1.69M 0.55%
+115,000
New +$1.67M
STRO icon
33
Sutro Biopharma
STRO
$353M
$1.4M 0.45%
13,933
– –
MRSN
34
DELISTED
Mersana Therapeutics
MRSN
$1.34M 0.43%
+2,880
New +$1.46M
FOLD
35
DELISTED
Amicus Therapeutics
FOLD
$1.34M 0.43%
94,600
– –
CCXI
36
DELISTED
ChemoCentryx, Inc.
CCXI
$1.29M 0.42%
23,600
-168,000
-88% -$9.04M
ALLK
37
DELISTED
Allakos
ALLK
$1.28M 0.41%
15,700
– –
ARNA
38
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.23M 0.4%
16,500
– –
GBT
39
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.2M 0.39%
21,800
+12,000
+122% +$763K
NKTR icon
40
Nektar Therapeutics
NKTR
$2.55B
$1.11M 0.36%
4,467
– –
EXAS
41
DELISTED
Exact Sciences
EXAS
$1.09M 0.35%
10,700
– –
INSM icon
42
Insmed
INSM
$26.5B
$1.08M 0.35%
33,600
– –
QURE icon
43
uniQure
QURE
$3.44B
$1.01M 0.33%
27,500
– –
GWPH
44
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$993K 0.32%
10,200
– –
DCPH
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$872K 0.28%
17,000
– –
KYNB
46
Kyntra Bio
KYNB
$32.4M
$810K 0.26%
788
– –
AGIO icon
47
Agios Pharmaceuticals
AGIO
$2.05B
$752K 0.24%
21,500
– –
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$637K 0.21%
24,800
+1,800
+8% +$41.1K
BLUE
49
DELISTED
bluebird bio
BLUE
$593K 0.19%
849
– –
CYTK icon
50
Cytokinetics
CYTK
$10.8B
$541K 0.17%
+25,000
New +$585K
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2020 Portfolio in Review

As of Q3 2020, International Biotechnology Trust held 58 positions worth $310M, up 3% from $301M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

International Biotechnology Trust's Q3 2020 filing shows 5 new, 12 increased, 7 reduced and 5 closed positions. Its largest new stake was Iovance Biotherapeutics: 145,000 shares worth $4.77M. The largest sale was Immunomedics Inc, an estimated $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2020 buy was Iovance Biotherapeutics: 145,000 shares worth $4.77M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q3 2020, an estimated $13.4M increase.
  • International Biotechnology Trust's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $20.1M.
  • International Biotechnology Trust fully exited Zogenix, Inc. in Q3 2020, selling an estimated $6.17M.
  • International Biotechnology Trust's ten largest holdings make up 58% of its $310M portfolio in Q3 2020.
  • International Biotechnology Trust opened 5 new positions and closed 5 in Q3 2020.
  • International Biotechnology Trust's portfolio value rose 3% quarter-over-quarter to $310M.

Based on International Biotechnology Trust's 13F filing for Q3 2020, filed 1 Dec 2020.